Abdullah Osman
Featured in: 
tmc.edu
Articles
-
Aug 14, 2024 |
digitalcommons.library.tmc.edu | Wangie Yu |Yunyun Chen |Nagireddy Putluri |Abdullah Osman
BACKGROUND: Cisplatin (CDDP) is a mainstay treatment for advanced head and neck squamous cell carcinomas (HNSCC) despite a high frequency of innate and acquired resistance. We hypothesised that tumours acquire CDDP resistance through an enhanced reductive state dependent on metabolic rewiring.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →